|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.
With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
Read
our publications on the go in the Samedan app for iPhone and iPad. You
can download issues for offline reading and our archives go as far back
as 2008! Download for free on the App Store. 
|
|
|
|
|
|
Widgets Magazine
Widgets Magazine
 |
Industry Events |
 |
PPMA SHOW 2018
25-27 September 2018, NEC, Birmingham, UK
The UK’s leading production line event is celebrating
its 30th Anniversary. Taking place at the NEC, Birmingham from 25-27
September 2018, the exhibition showcases the latest processing and packaging
machinery. Attended by thousands of manufacturers of food, pharmaceuticals and
FMCG as well as contract packers and more.
More info >> |
|
 |
News and Press Releases |
 |
BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions
BioIVT, a leading provider of biospecimens and related services, today
announced that it will be hosting a webinar entitled “Whole-cell In
Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions
(HDIs)” at 11 am ET on June 20.
More info >> |
|
 |
White Papers |
 |
|
Soothing the Logistical Headache of Clinical Trials
Equilibrium Travel Management
As many as 30 per cent of subjects on phase three clinical studies drop out. Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial. It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >> |
|
|
